The blood–brain barrier (BBB) inhibits most medications from reaching the brain. The epithelial-like tight junctions inside the brain capillary endothelium are responsible for this feature. The BBB is physically and physiologically separate from the choroid plexus' blood–cerebrospinal fluid barrier. The blood-brain barrier (BBB) is a dynamic structure that acts as a gatekeeper and reflects the brain's specific requirements. The presence of the BBB makes developing novel medicines for brain diseases or new radiopharmaceuticals for brain imaging challenging. Biotechnology produces only large molecule medications that do not cross the BBB. While it is commonly considered that small molecules travel freely through the BBB, only about 98 percent of all small molecules do so.
Title : Mucoadhesive electrospun fibrous systems for the fast and sustained delivery of drugs
Luis Jesus Villarreal Gomez, Autonomous University of Baja California, Mexico
Title : Pharmaceutics 2023, Singapore, Abstract Pathology and Patient Safety: The Vital Role of Electronic Medical Record and Pathology Informatics in Error Reduction and Precision Medicine
Consolato M Sergi, University of Ottawa, Canada
Title : Values based practice and the impact on Drug discovery, regulation of the Pharma industry and consent in healthcare”
Ashok Handa, Collaborating Centre for Values Based Practice, United Kingdom